SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response									

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schroeder Thilo					2. Issuer Name and Ticker or Trading Symbol <u>Revolution Medicines, Inc.</u> [RVMD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify					
	(Fi VOLUTION GINAW DR		3. Date of Earliest Transaction (Month/Day/Year) 03/17/2022								below		e 	Other below				
(Street) REDWC CITY	DOD CA	A	94063	3	4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								 6. Individual or Joint/Group Filing (Check Appli Line) X Form filed by One Reporting Person Form filed by More than One Reportin Person 				
(City)	(St	ate)	(Zip)															
		Tab	le I - N	lon-Deriva	ative	1		-	d, D	-				y Own	ed			
1. Title of s	Security (Ins	tr. 3)		2. Transactic Date (Month/Day/				3. Transaction Code (Instr. 8)		4. Securities Disposed Of	(D) (Inst	d (A) or r. 3, 4 a	and 5) Securiti Benefici Owned Reporte		es ially Following ed	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				
Common	Stock			03/17/20	22			Р		10,120	A	\$18.	78(1)	538	3,295		I	By Nextech Crossover I SCSP ⁽²⁾
Common	Stock			03/18/20	22			Р		5,992	A	\$19.	28 ⁽³⁾	544	I,287		I	By Nextech Crossover I SCSP ⁽²⁾
Common	Stock			03/18/20	22			Р		76,208	A	\$20.	<mark>38</mark> ⁽⁴⁾	620),495		I	By Nextech Crossover I SCSP ⁽²⁾
Common	Stock			03/21/20	22			Р		74,852	A	\$20.	73 ⁽⁵⁾	695	i,347		I	By Nextech Crossover I SCSP ⁽²⁾
Common Stock		03/21/2022				Р		879	A	\$21.	22 ⁽⁶⁾	696	5,226		I	By Nextech Crossover I SCSP ⁽²⁾		
Common Stock												2,66	8,214		I	By Nextech V Oncology S.C.S., SICAV- SIF ⁽⁷⁾		
Common Stock												300),000		I	By Nextech VI Oncology SCSp ⁽⁸⁾		
		т	able I	I - Derivat (e.g., pt						posed of, convertik				Ownee	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Yea	r) if an	. Deemed ecution Date,		4. Transaction Code (Instr. 8) 5. Number of Derivativ Securitie Acquired (A) or Disposed of (D) (Instr. 3, and 5)		r 6. Date Exercisable and Expiration Date (Month/Day/Year) S			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. De Se (Ir	8. Price of Derivative Security Instr. 5) 9. Numbe derivative Security Beneficia Owned Following Reported Transacti (Instr. 4)		e s Illy J	10. Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownershi (Instr. 4)

		Tal	ole II - Derivati	ve Se	curit	ies	Acqu	ired, Disp	osed of,	or Be	nenena	ly Owne	d		
			(e.g., pı	its, ca	ills, v	varr	ants,	options, o		le se	ciurities)			
1. Title of	2.	3. Transaction	3A. Deemed	4.ode	V	(A)N	um(D);r	Date ExDectis Elatero			eSalnaares		9. Number of	10.	11. Nature
	Conversion	estonth/Dav/Year)	Execution Date, if any	Code (Deri	vative	Expiration Da (Month/Dav/Y		Amou Secu		Derivative Security	derivative Securities	Ownership Form:	of Indirect Beneficial
(Instr. 3) 1. The price r	Price of eported in Colu	umn 4 is a weighted a	(Month/Day/Year) average price. These	8) shares w	ere pur	Sec	urities	tiple transaction	ns at prices ra	Unde	rlying 1011 \$18.37	to \$19:13 inc	Beneficially	Direct (D)	Ownership demakes to (Instr. 4)
provide to the	Security se	curity holder of the l	ssuer, or the staff of t	he Secur	ities an	d (A) c	hange C	Commission, up	on request, fu	Secu	nation stiga	rding the nun	nber of shares pur	hased at each	separate '
		rth in this footnote.					osed			. 3 and	4)		Reported		.
2 Nextech In	vest AG is the	investment advisor o	• of Nextech Crossover		("Nexte			• ") The reportir	o nerson is a			• at Nextech Ir		• therefore he d	eemed to

12. Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech"(dvssover"). The reporting person is a managing member at Nextech Investment advisor of Nextech Crossover. The reporting person dis dvs field adversation of shares held by Nextech Crossover. The reporting person dis dvs field adversation of shares held by Nextech Crossover. The reporting person dis dvs field adversation of shares held by Nextech Crossover. The reporting person dis dvs field adversation of such shares, except to the extent of any pecultary filterest therein. and 3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$18.77 to \$19.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$19.78 to \$20.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full inform**Amoung**arding the number of shares purchased at each separate price within the range set forth in this footnote. or

5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple ransactions reprize and row 520.21 to \$21.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Correctives and reprize to the reported by the

6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$21.21 to \$21.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

7. Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

8. Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Remarks:

/s/ Darren DeStefano,

Attorney-in-Fact

03/21/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.